Another study also described that, after 6 months of ω-3 supplementation, hepatic echogenicity and insulin sensitivity were significantly improved in children with NAFLD, although no change in serum ALT or BMI was observed [155]. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.